This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.
• Subjects must voluntarily sign and date an informed consent, ap-proved by an independent ethics committee (IEC)/institutional review board (IRB)
Documented diagnosis of CLL at time point of inclusion in a first-line study of the GCLLSG (development of RT is not an exclusion criterion)
First-line treatment was administered within one of these first-line studies of the GCLLSG (CLL13, CLL14, or CLL17).
Subsequent therapy lines were either documented during the participa-tion in a first-line study of the GCLLSG or patient consented to have the subsequent therapy lines documented within this observational trial.
• Patients without participation in one of the first-line studies of the GCLLSG (CLL13, CLL14, CLL17)
Subjects with legal incapacity
Subjects who are institutionalized by regulatory or court order
Subjects who are in dependence to the sponsor or the investigator
German CLL Study Group
Lead sponsor
GELLC (Grupo Español de Leucemia Linfocítica Crónica)
Collaborator
Nordic Lymphoma Group
Collaborator
Polish Adult Leukemia Group
Collaborator
HOVON - Dutch Haemato-Oncology Association
Collaborator